Roger Harrison to Breast Neoplasms
This is a "connection" page, showing publications Roger Harrison has written about Breast Neoplasms.
Connection Strength
1.549
-
Immunogenic Treatment of Metastatic Breast Cancer Using Targeted Carbon Nanotube Mediated Photothermal Therapy in Combination with Anti-Programmed Cell Death Protein-1. J Pharmacol Exp Ther. 2024 Jun 21; 390(1):65-77.
Score: 0.635
-
Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy. PLoS One. 2013; 8(10):e76403.
Score: 0.302
-
Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine. Cancer Lett. 2011 Aug 01; 307(1):53-61.
Score: 0.256
-
Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration. Anticancer Res. 2006 May-Jun; 26(3A):1745-51.
Score: 0.181
-
Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature. Cancer Invest. 2013 Oct; 31(8):505-10.
Score: 0.076
-
Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Cancer Lett. 2011 Feb 28; 301(2):177-84.
Score: 0.062
-
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation. Cancer Chemother Pharmacol. 2003 Oct; 52(4):270-6.
Score: 0.037